Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Proscience Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$7,986,004

402 payments

Through program year 2025, Proscience Research Group LLC is reported as receiving $7,986,004 in research payments, across 402 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $175,810 22
2024 Research $81,034 9
2023 Research $444,813 22
2022 Research $3,600,297 65
2021 Research $1,436,436 72
2020 Research $906,790 108
2019 Research $1,340,824 104

Breakdown

Who paid Research payments · program years 2019–2025
  1. ITI, Inc. $4,086,219 66 payments
  2. Allergan Inc. $2,058,387 181 payments
  3. Hoffmann-La Roche Limited $816,396 22 payments
  4. Teva Pharmaceuticals USA, Inc. $350,701 60 payments
  5. Vanda Pharmaceuticals Inc. $240,054 7 payments
  6. Biogen, Inc. $103,666 4 payments
  7. BioXcel Therapeutics, Inc. $94,634 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $82,981 15 payments
  9. AbbVie, Inc. $42,347 9 payments
  10. Tolmar, Inc. $28,292 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia $4,005,405 57 payments
  2. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $860,858 37 payments
  3. Acute Schizophrenia Study $816,396 22 payments
  4. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $469,278 38 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $314,622 46 payments
  6. Evaluation of Efficacy and Safety of Iloperidone in the Treatment of Bipolar I Disorder $240,054 7 payments
  7. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $214,211 29 payments
  8. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $171,692 13 payments
  9. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current $129,012 18 payments
  10. A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $102,566 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record